



ArQule, Inc.  
Investor Relations Department  
One Wall Street  
Burlington, MA 01803  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

#### NASDAQ: ARQL

Last Trade:	1.43
Trade Time:	4:00 PM ET Nov 22, 2017
Change:	0.02  (+1.418%)
Day Range	1.37 - 1.43
52-Week Range	0.92 - 1.68
Volume	253,831


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and certain rare diseases. Our mission is to discover, develop and commercialize novel small molecule drugs that will dramatically extend and improve the lives of patients in areas of high unmet need. ArQule is delivering on the potential of precision medicine by providing its patients with novel therapies for multiple hard to treat indications and its shareholders with a focused, highly efficient and cost effective research and development strategy.

ArQule i... [\(more\)](#)

## Stock Information



## Press Releases [\[ View all \]](#)

- Nov 21, 2017  
[ArQule Announces Dosing in a Registrational Trial of FGFR Inhibitor, Derazantinib, for Treatment of Intrahepatic Cholangiocarcinoma](#)
- Nov 9, 2017  
[ArQule Reports Third Quarter 2017 Financial Results](#)
- Nov 8, 2017  
[ArQule Announces \\$9.5 Million Private Placement of Preferred Stock](#)
- Nov 1, 2017  
[FDA Grants Rare Pediatric Disease Designation to ArQule's Miransertib \(ARQ 092\) for the Treatment of Proteus Syndrome](#)
- Oct 26, 2017  
[ArQule To Report Third Quarter 2017 Financial Results On November 9, 2017](#)

## Financials [\[ View all \]](#)

- [Third Quarter Financial Results](#)
- Mar 9, 2017  
[Annual Report \(10-K\)](#)
- Apr 13, 2017  
[Proxy Statement \(DEF 14A\)](#)
- Nov 9, 2017  
[Quarterly Report \(10-Q\)](#)
- Aug 4, 2017  
[Quarterly Report \(10-Q\)](#)
- May 3, 2017  
[Quarterly Report \(10-Q\)](#)